October 28, 2011 07:27 ET

U.S. Cardiac Marker Diagnostic Testing Market to Surpass $2.4 Billion by 2016

NEW YORK, NY--(Marketwire - Oct 28, 2011) - cites in its newly published "Cardiac Marker Diagnostic Testing Markets" report that the U.S. cardiac marker diagnostic testing market will surpass $2.4 billion by 2016. For more information, visit:

Both the U.S. and the world market for cardiac marker diagnostic testing are expected to grow at roughly 8% compound annual growth rates through 2016. Key growth areas include the cardiac rapid assay market, troponins, Creatine kinase-myocardial band (CK-MB) and brain natriuretic peptide (BNP) testing. Significant cardiac marker diagnostic testing growth is also anticipated internationally, particularly in the European Union, where Germany, Italy and France each showed significant cardiac marker revenue in 2010.

The "Cardiac Marker Diagnostic Testing Markets" report covers:

  • Acute myocardial infarction (AMI).
  • Heart failure.
  • BNP.
  • Myoglobin.
  • Homocysteine (Hcy).
  • C-reactive protein (CRP).
  • Pulmonary embolism (PE) (D-dimer test).
  • Low-density and high-density lipoproteins (LDL and HDL).
  • Stroke.
  • CK-MB and cardiac enzymes.
  • Albumin.
  • Cardiac markers used in clinical decisions.
  • Cardiac markers in renal failure.
  • Troponins in non-ischemic heart disease.
  • Cardiac panels.
  • Point of care (POC) cardiac markers.

The "Cardiac Marker Diagnostic Testing Markets" report examines companies manufacturing cardiac marker equipment and supplies in the world. Companies covered include: Abbott, Alere, Ani, Axis-Shield, Bayer, Beckman Coulter, Biosite, Johnson & Johnson, LifeSign, PreMD, Randox, Response, Roche, Siemens, Sierra Resources and Spectral Diagnostics.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit:

About is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Contact Information